Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 5/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12725244 | 0.94 | KDM4E (0.44) | ADORA2AADORA1KDM4EKMT2AMEN1 | |
| SCHEMBL12725028 | 0.92 | ADORA2A (0.43) | ADORA2AADORA1KDM4EKMT2AMEN1 | |
| SCHEMBL1631799 | 0.91 | ADORA2A (0.44) | ADORA2AADORA1KDM4EKMT2AMEN1 | |
| SCHEMBL1630415 | 0.91 | ADORA2A (0.41) | ADORA2AADORA1KDM4EKMT2AMEN1 | |
| SCHEMBL12725389 | 0.91 | ADORA2A (0.41) | ADORA2AADORA1KDM4EKMT2AMEN1 | |
| SCHEMBL1631073 | 0.90 | ADORA2A (0.42) | ADORA2AADORA1KDM4EKMT2AMEN1 | |
| SCHEMBL4966585 | 0.90 | MEN1 (0.41) | ADORA2AADORA1KDM4EKMT2AMEN1 | |
| SCHEMBL1629641 | 0.89 | ADORA2A (0.44) | ADORA2AADORA1KDM4EKMT2AMEN1 | |
| SCHEMBL1632418 | 0.89 | ADORA2A (0.41) | ADORA2AADORA1KDM4EKMT2AMEN1 | |
| SCHEMBL1630181 | 0.89 | ADORA2A (0.41) | ADORA2AADORA1KDM4EKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932270-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-7932270-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-20090012126-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2009-01-08 | — | — | US | disclosed |
| US-20090012126-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2009-01-08 | — | — | US | disclosed |
| US-20090012126-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2009-01-08 | — | — | US | disclosed |
| WO-2008016643-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012126-A1 | Certain chemical entities, compositions, and methods | MYLK, MYH2, MYH10 | ADORA2A 2369/4885ADORA1 2532/4885KDM4E 3309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.